GSK advances mRNA flu vaccine to late-stage trial after strong mid-stage results
GSK will advance its mRNA-based seasonal influenza vaccine to late-stage trials after mid-stage data showed it generated stronger immune responses than currently approved flu vaccines.
2 sourcesClinical trials
00